After the failure of ENHANCEd cholesterol lowering in familial hypercholesterolemia, SEAS of problems with ezetimibe

Angiology

Volumn 60, Issue 1, 2009, Pages 127-128

  Mascitelli, Luca ^a   Ravnskov, Uffe ^b   Pezzetta, Francesca ^b   Goldstein, Mark R ^a  

^a Medical Service   (Italy)

^b Ospedale di Tolmezzo ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN;

AORTA STENOSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; ISCHEMIC HEART DISEASE; LETTER; TREATMENT FAILURE;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; BLOOD COAGULATION; CHOLESTEROL; CORONARY DISEASE; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIMVASTATIN; TREATMENT FAILURE;

EID: 59149086732     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319708327788     Document Type: Letter

References (11)

1. Whayne TF Jr. Is there a problem with ezetimibe or just ENHANCEd hype? Angiology. 2008 Sep 15 [Epub ahead of print].
2. Pedone C., Carbonin P., Kastelein JJ, et al. ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008 ; 358: 1431-1443.
3. Jansen AC, van Aalst-Cohen ES, Tanck MW, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med. 2004 ; 256: 482-490.
4. de Sauvage Nolting PR, Defesche JC, Buirma RJ, Hutten BA, Lansberg PJ, Kastelein JJ Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia. J Intern Med. 2003 ; 253: 161-168.
5. Sugrue DD, Trayner I., Thompson GR, et al. Coronary artery disease and haemostatic variables in heterozygous familial hypercholesterolaemia. Br Heart J. 1985 ; 53: 265-268.
6. Jansen AC, van Aalst-Cohen ES, Tanck MW, et al, Genetic determinants of cardiovascular disease risk in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2005 ; 25: 1475-1481.
7. Rossebø AB, Pedersen TR, Boman K., et al. for the SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008 ; 359: 1343-1356.
8. Goldstein MR, Mascitelli L., Pezzetta F. The double-edged sword of statin immunomodulation. Int J Cardiol. 2008 May 15 [Epub ahead of print].
9. Shepherd J., Blauw GJ, Murphy MB, et al, and the PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002 ; 360: 1623-1630.
10. Bradford PG, Awad AB Phytosterols as anticancer compounds. Mol Nutr Food Res. 2007 ; 51: 161-170.
11. Ravnskov U. Re: the association between statins and cancer incidence in a veterans population. J Natl Cancer Inst. 2008 ; 100: 972-973.